Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 11—November 2020
Research Letter

Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020

Amy K. FeehanComments to Author , Daniel Fort, Julia Garcia-Diaz, Eboni G. Price-Haywood, Cruz Velasco, Eric Sapp, Dawn Pevey, and Leonardo Seoane
Author affiliations: Ochsner Clinic Foundation, New Orleans, Louisiana, USA (A.K. Feehan, D. Fort, J. Garcia-Diaz, E.G. Price-Haywood, C. Velasco, D. Pevey, L. Seoane); University of Queensland Ochsner Clinical School, New Orleans (A.K. Feehan, J. Garcia-Diaz, E.G. Price-Haywood, L. Seoane); Public Democracy, Arlington, Virginia, USA (E. Sapp); Louisiana State University Health Science Center–Shreveport, Shreveport, Louisiana, USA (L. Seoane)

Main Article

Table

Prevalence of SARS-CoV-2 infection and COVID-19–related IFR after 7 weeks of an active stay-at-home order, by race/ethnicity, 10 sites in Orleans and Jefferson Parishes, Louisiana, USA, May 9–15, 2020*

Value Total White Black Asian Native American Pacific Islander Multiracial or other Hispanic†
Positive, no./total no. (%)
183/2,640
(100)
79/1,607
(60.9)
90/828
(31.4)
9/130
(4.9)
0/14
(0.5)
0/3
(0.1)
5/58
(2.2)
18/293
(11.1)
Orleans/Jefferson Parish residents, no. (%)
825,057
(100)
419,800 
(50.8)
356,925
(43.2)
29,740
(3.6)
4,088
(0.5)
495
(0.1)
14,009
(1.7)
86,289
(10.5)
Unadjusted exposure‡
6.9
(6.0–8.0)
4.9
(3.9–6.1)
10.9
(8.8–13.2)
6.9
(3.2–12.7)
0
0
8.6
(2.9–19.0)
6.1
(3.7–9.5)
Weighted exposure§
7.8
(7.8–7.9)
5.9
(5.8–5.9)
10.3
(10.2–10.4)
6.4
(6.1–6.7)
0
0
9.4
(9.0–10.0)
7.5
(7.3– 7.7)
Weighted point prevalence¶
1.0
(0.6–1.3)
1.3
(0.8–1.9)
0.5
(0–1.0)
0.9
(0–2.6)
0
0
2.2
(0–5.9)
2.2
(0.5–3.8)
Weighted seroprevalence#
6.9
(6.8–6.9)
4.5
(4.4–4.6)
9.8
(9.7–9.9)
5.5
(5.2–5.7)
0
0
7.1
(6.7–7.6)
5.3
(5.2–5.5)
No. presumed recovered**
56,578
18,975
34,973
1,629


1,001
4,582
No. deaths as of May 16, 2020
925
299
600
10
0
2
14
Unknown
IFR†† 1.61
(1.5–1.7) 1.55
(1.4–1.7) 1.69
(1.6–1.8) 0.61
(0.3–1.1)‡‡ 1.38
(0.8–2.3)

*Values are % (95% CI) except as indicated. The 2018 population estimates and deaths by race reported by the Louisiana Department of Public Health (4). Deaths are deemed to be COVID-19–related and have an associated confirmed PCR-positive test. Probable COVID-19 deaths without a positive PCR test were not included in these counts. By May 16, a total of 13,666 state-aggregated, confirmed cases had been reported in both parishes. COVID-19, coronavirus disease; IFR, infection fatality ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; –, calculated value would be unreliable given low sample.
†Hispanic ethnicity is a separate analysis and numbers were not subtracted from race. Hispanic deaths were not being reported as of May 16, 2020 (4). ‡Percentage of the sample with a PCR-positive test, an IgG-positive test, or both.
§Census-weighted percentage of a PCR-positive test, an IgG-positive test, or both calculated to match 2018 racial demographics by parish and then combined.
¶Census-weighted percentage of PCR-positive and IgG-postive tests calculated to match 2018 racial demographics by parish and then combined.
#Census-weighted percentage of IgG-positive tests calculated to match 2018 racial demographics by Parish and then combined.
**Number of residents multiplied by weighted seroprevalence (IgG-positive tests).
††IFR equals the number of deaths per number of persons presumed recovered from SARS-CoV-2 infection plus deaths.
‡‡Significantly lower than White (p = 0.0034), Black (p = 0.0013), and multiracial or other (p = 0.0467) persons.

Main Article

Page created: July 28, 2020
Page updated: October 19, 2020
Page reviewed: October 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external